#1 Clinical Trials Search in Europe

CEFTAROLINE FOSAMIL

Ceftaroline fosamil (marketed as Teflaro® or Zinforo®) is an advanced cephalosporin antibiotic that has been studied in various clinical trials for treating bacterial infections. Unlike traditional cephalosporins, ceftaroline has expanded activity against resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This article explores how ceftaroline fosamil has been used in clinical trials for various conditions, including community-acquired pneumonia, skin infections, bloodstream infections, and special patient populations such as children and those with renal impairment.

# Ceftaroline Fosamil: A Comprehensive Guide for Patients Table of Contents – [What is Ceftaroline Fosamil?](#what-is-ceftaroline-fosamil) – [How Ceftaroline Fosamil Works](#how-ceftaroline-fosamil-works) – [Medical Conditions Treated with Ceftaroline Fosamil](#medical-conditions-treated-with-ceftaroline-fosamil) – [Administration and Dosage](#administration-and-dosage) – [Effectiveness of Ceftaroline Fosamil](#effectiveness-of-ceftaroline-fosamil) – [Side Effects and Safety Information](#side-effects-and-safety-information) – [Special Populations](#special-populations) – [Current Research and Emerging Uses](#current-research-and-emerging-uses) What is Ceftaroline Fosamil? Ceftaroline fosamil is an antibiotic medication that belongs to the cephalosporin family, specifically classified as a fifth-generation cephalosporin. It is commercially available under several brand names, including Teflaro® and Zinforo®. Other scientific and development names include PPI-0903, TAK-599, TAK599, and PPI0903 [1][2]. What makes ceftaroline fosamil special is its ability to work against bacteria that have become resistant to other commonly used antibiotics. It has a broader spectrum of activity compared to earlier generations of cephalosporins, particularly against certain hard-to-treat bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) [3]. How Ceftaroline Fosamil Works Ceftaroline fosamil is what’s known as a “prodrug.” This means that after it enters your body, it gets converted into its active form called ceftaroline. This conversion happens through enzymes called phosphatases that are present in your plasma [4]. Once activated, ceftaroline works by binding to proteins called penicillin-binding proteins (PBPs) in bacterial cell walls. This binding prevents bacteria from forming their protective cell walls properly, which ultimately leads to bacterial cell death. What’s particularly notable about ceftaroline is its ability to bind to a modified penicillin-binding protein called PBP2a, which is responsible for methicillin resistance in Staphylococcus aureus bacteria [3]. The body primarily eliminates ceftaroline through the kidneys, with an elimination half-life of approximately 2.6 hours in adults with normal kidney function [4]. Medical Conditions Treated with Ceftaroline Fosamil Ceftaroline fosamil has been approved by regulatory agencies, including the U.S. Food and Drug Administration (FDA), for the treatment of several types of infections: # Community-Acquired Bacterial Pneumonia (CABP) This is a type of lung infection that develops outside of hospitals or healthcare facilities. Ceftaroline fosamil is used to treat adults and children with CABP, particularly when there is a risk that the infection might be caused by resistant bacteria [1][5]. # Acute Bacterial Skin and Skin Structure Infections (ABSSSI) These are serious skin infections that involve deeper tissue or require significant surgical intervention. Examples include major abscesses, wound infections, and cellulitis (infection of the skin and the tissue beneath it) [2][5]. # Complicated Skin and Soft Tissue Infections (cSSTI) Similar to ABSSSI, these are serious infections of the skin and underlying tissues. Ceftaroline fosamil is particularly valuable when these infections are caused by or suspected to be caused by MRSA [2]. # Investigational Uses Research is ongoing to evaluate ceftaroline fosamil’s effectiveness for other types of infections, including: – **Staphylococcus aureus Bacteremia**: Infections where bacteria enter the bloodstream [3]. – **Bone and Joint Infections**: Including osteomyelitis (bone infection) and joint infections [2]. – **Meningitis and Central Nervous System Infections**: Limited research is examining whether ceftaroline can penetrate into cerebrospinal fluid to treat infections in the brain or spinal cord [6][7]. Administration and Dosage Ceftaroline fosamil is administered as an intravenous (IV) infusion, which means it’s given directly into a vein. It cannot be taken orally as a pill or liquid [1]. # Standard Adult Dosing For adults with normal kidney function, the typical dose is: – 600 mg administered intravenously over 60 minutes, every 12 hours for standard infections [1]. – For more severe infections or those caused by resistant bacteria, dosing may be adjusted to 600 mg every 8 hours [3]. # Pediatric Dosing Dosing for children is based on age and weight: – Children aged 2 months to less than 2 years: 8-10 mg/kg every 8 hours – Children aged 2 years to less than 18 years: 12-15 mg/kg (up to a maximum of 600 mg) every 8 hours [2][8]. # Dose Adjustments The dose may need to be adjusted for patients with reduced kidney function. For patients with end-stage renal disease or those undergoing hemodialysis, the dose is typically reduced to 200 mg [9]. # Duration of Treatment The length of treatment depends on the type and severity of infection: – For skin infections: typically 5 to 14 days – For pneumonia: typically 5 to 7 days [1][5]. Effectiveness of Ceftaroline Fosamil Clinical studies have demonstrated that ceftaroline fosamil is effective for its approved uses. In trials comparing ceftaroline fosamil to other antibiotics: # For Community-Acquired Bacterial Pneumonia Clinical studies have shown that ceftaroline fosamil is at least as effective as ceftriaxone (another commonly used antibiotic) for treating CABP. In some studies, ceftaroline showed superior results [5][10]. # For Skin Infections For complicated skin infections, clinical trials have shown that ceftaroline fosamil has similar effectiveness to vancomycin plus aztreonam (a common combination therapy for these infections) [5]. # Against Resistant Bacteria Ceftaroline fosamil has shown effectiveness against MRSA, which is a significant advantage over many other antibiotics. It is also effective against penicillin-resistant Streptococcus pneumoniae, another concerning resistant pathogen [3]. Side Effects and Safety Information Like all medications, ceftaroline fosamil can cause side effects, although not everyone experiences them. # Common Side Effects The most frequently reported side effects include: – Diarrhea – Nausea – Rash – Fever – Reactions at the injection site [1][5]. # Serious Side Effects Though less common, more serious side effects can include: – **Allergic reactions**: Including anaphylaxis (severe, potentially life-threatening allergic reaction) – **Clostridium difficile-associated diarrhea**: A potentially serious intestinal condition – **Blood disorders**: Such as decreases in certain blood cell counts – **Kidney problems**: Particularly in those with pre-existing kidney disease [3][5]. # Drug Interactions Ceftaroline fosamil appears to have fewer drug interactions compared to some other antibiotics. However, it’s always important to inform your healthcare provider about all medications you are taking [5]. Special Populations # Elderly Patients Studies have shown that ceftaroline fosamil is generally safe and effective in elderly patients (≥ 65 years). Some dose adjustment may be necessary based on kidney function, which naturally declines with age [1]. # Pediatric Patients Ceftaroline fosamil has been studied and approved for use in children as young as 2 months of age. Dosing is adjusted based on age and weight [2][8]. # Pregnant and Breastfeeding Women Limited data are available regarding the use of ceftaroline fosamil during pregnancy and breastfeeding. The decision to use it should involve careful consideration of the potential benefits versus risks [5]. # Patients with Kidney Problems Ceftaroline fosamil is primarily eliminated through the kidneys. Therefore, patients with impaired kidney function may require dose adjustments. For patients with end-stage renal disease, including those on hemodialysis, specific dosing regimens have been established [9]. Current Research and Emerging Uses Ongoing research is exploring additional potential uses for ceftaroline fosamil: # Bone and Joint Infections Studies are investigating the effectiveness of ceftaroline fosamil for treating osteomyelitis (bone infection) and infected joints, including those with prosthetic implants [2]. # Central Nervous System Infections Research is examining whether ceftaroline can effectively penetrate into cerebrospinal fluid to treat meningitis and other central nervous system infections [6][7]. # Combination Therapy Studies are looking at combining ceftaroline fosamil with other antibiotics for treating particularly difficult infections or to prevent the development of resistance [3]. # Use in Cystic Fibrosis Research is investigating how ceftaroline behaves in patients with cystic fibrosis, who often have unique needs regarding antibiotic therapy due to the nature of their lung infections [11]. # Late-Onset Sepsis in Neonates Studies are examining the safety and effectiveness of ceftaroline fosamil for treating serious bloodstream infections in newborns [8]. In conclusion, ceftaroline fosamil represents an important addition to our antibiotic arsenal, particularly for infections caused by resistant bacteria. As with all antibiotics, it should be used appropriately to maintain its effectiveness and minimize the development of resistance.
Aspect Details
Drug Name Ceftaroline fosamil (marketed as Teflaro®, Zinforo®)
Drug Class Fifth-generation cephalosporin antibiotic
Key Advantages Active against MRSA and other resistant gram-positive bacteria while maintaining gram-negative coverage
Approved Indications Community-acquired bacterial pneumonia (CABP), Acute bacterial skin and skin structure infections (ABSSSI)
Investigational Uses Bacteremia, Osteomyelitis, Joint infections, Meningitis/ventriculitis, Late-onset sepsis in neonates
Adult Dosing 600 mg IV every 12 hours (q12h) for standard infections; 600 mg IV every 8 hours (q8h) for severe infections
Pediatric Dosing Age ≥6 months: 12-15 mg/kg IV every 8 hours (up to 600 mg) Age <6 months: 8-10 mg/kg IV every 8 hours
Special Populations Dose adjustment needed for renal impairment; Studies conducted in elderly patients, children, patients with cystic fibrosis
Common Side Effects Diarrhea, nausea, rash, elevated liver enzymes
Administration Intravenous infusion over 60 minutes (for standard 12-hour dosing) or 120 minutes (for 8-hour dosing)
Pharmacokinetics Volume of distribution ~20L, 20% protein binding, primarily renally eliminated, half-life ~2.6 hours in patients with normal renal function
Efficacy Measures Clinical cure rates comparable to standard therapies (vancomycin, ceftriaxone) in clinical trials; Time to clinical stability in pneumonia; Lesion size reduction in skin infections

FAQ

  • What types of infections can ceftaroline fosamil treat? Clinical trials show that ceftaroline fosamil is effective against several types of bacterial infections. It's primarily used for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). It has also been studied for treating bloodstream infections (bacteremia), including those caused by methicillin-resistant Staphylococcus aureus (MRSA), bone and joint infections including osteomyelitis, and certain infections in pediatric patients. Its broad-spectrum activity covers many gram-positive and some gram-negative bacteria, though it lacks significant activity against Pseudomonas aeruginosa and certain other resistant gram-negative pathogens.
  • How is ceftaroline fosamil administered to patients? Ceftaroline fosamil is administered as an intravenous (IV) infusion. The standard adult dose is typically 600 mg infused over 60 minutes every 12 hours, though some studies have used 600 mg every 8 hours for more severe infections. For pediatric patients, dosing is weight-based, ranging from 8-15 mg/kg depending on age and infection type. In patients with impaired kidney function, dose adjustments are necessary. The duration of treatment varies by infection type, typically ranging from 5-14 days for pneumonia and skin infections, and potentially longer for more complex infections like osteomyelitis or bacteremia.
  • What makes ceftaroline different from other antibiotics? Ceftaroline stands out from other cephalosporins and antibiotics due to its expanded spectrum of activity against resistant gram-positive bacteria, particularly MRSA. Most other cephalosporins cannot effectively treat MRSA infections. Ceftaroline works by binding to penicillin-binding proteins (including PBP2a in MRSA) to inhibit bacterial cell wall synthesis. Clinical trials have shown it to be as effective as combination therapies (like vancomycin plus aztreonam) for certain infections, allowing for simplified treatment with a single agent. It generally has a favorable safety profile compared to some alternative treatments, with fewer monitoring requirements than drugs like vancomycin.
  • What are the common side effects of ceftaroline fosamil? Clinical trials indicate that ceftaroline fosamil is generally well-tolerated. Common side effects include diarrhea, nausea, and rash. Like other cephalosporins, it can cause allergic reactions, particularly in patients with penicillin allergies. Laboratory abnormalities may include elevated liver enzymes and changes in blood cell counts. Serious adverse events are uncommon but can include Clostridioides difficile-associated diarrhea. In clinical trials, discontinuation rates due to adverse events were generally low, and the safety profile was comparable to comparator antibiotics like vancomycin, ceftriaxone, and linezolid.
  • Can ceftaroline be used in children and special populations? Yes, clinical trials have studied ceftaroline in various special populations. For pediatric patients (from 2 months to 17 years), ceftaroline has been studied for treating skin infections and pneumonia with weight-based dosing. Studies have also examined its use in elderly patients with community-acquired pneumonia. For patients with renal impairment, dose adjustments are required based on creatinine clearance. Studies have specifically looked at ceftaroline pharmacokinetics in patients with end-stage renal disease undergoing hemodialysis. Additionally, research has examined its use in patients with augmented renal clearance (often seen in critically ill patients) and those with cystic fibrosis.

Ongoing Clinical Trials on CEFTAROLINE FOSAMIL

  • Comparing rifampin-free treatment versus rifampin in adults with staphylococcal prosthetic valve endocarditis

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Ceftaroline fosamil: A prodrug that is rapidly converted in the body to the active form ceftaroline. It is a fifth-generation cephalosporin antibiotic with activity against many resistant bacteria, including MRSA.
  • MRSA: Methicillin-Resistant Staphylococcus Aureus – a type of bacteria resistant to many antibiotics including methicillin and other common antibiotics. It can cause difficult-to-treat infections in different parts of the body.
  • Community-Acquired Bacterial Pneumonia (CABP): A lung infection that develops in people with limited or no contact with healthcare systems or settings. It's distinguished from hospital-acquired pneumonia, which develops during or after hospitalization.
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Bacterial infections of the skin and underlying tissues, including cellulitis, wound infections, and major abscesses. These infections often require antibiotic treatment.
  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious complications including sepsis if not treated promptly with appropriate antibiotics.
  • Osteomyelitis: An infection of bone that can be caused by bacteria or fungi. It often requires prolonged antibiotic treatment and sometimes surgical intervention.
  • Pharmacokinetics (PK): The study of how drugs move through the body, including absorption, distribution, metabolism, and excretion. PK studies help determine appropriate dosing regimens.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including mechanisms of action and relationship between drug concentration and effect.
  • Minimum Inhibitory Concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of a bacterium. Lower MIC values indicate that less drug is needed to inhibit the growth of the organism.
  • Clinical Cure: The complete resolution of all signs and symptoms of infection, or improvement to such an extent that no further antimicrobial therapy is necessary.
  • Augmented Renal Clearance: An increased removal of drugs through the kidneys, often seen in critically ill patients, which can lead to lower than expected drug concentrations and potentially reduced effectiveness.
  • Late-Onset Sepsis: A serious infection with systemic inflammation that occurs in newborns or infants after the first week of life, often requiring intensive antibiotic treatment.
  • Test of Cure (TOC): An assessment performed after completion of antibiotic therapy to determine if the infection has been successfully treated.
  • Modified Intent-to-Treat (MITT): A subset of the intent-to-treat population in clinical trials that includes only participants who meet certain criteria, such as having a confirmed bacterial infection.
  • End of Therapy (EOT): The point at which antibiotic treatment is completed, when patients are evaluated for initial response to treatment.
  • Cerebrospinal Fluid (CSF): The clear fluid that surrounds the brain and spinal cord, protecting them from injury. Antibiotics must penetrate into CSF to treat central nervous system infections.
  • Ventriculitis: Inflammation or infection of the ventricles of the brain, which are fluid-filled cavities that produce cerebrospinal fluid.
  • Cystic Fibrosis (CF): A genetic disorder that affects mostly the lungs and digestive system, leading to frequent respiratory infections that often require specialized antibiotic treatment.

References

  1. https://clinicaltrials.gov/study/NCT01666743
  2. https://clinicaltrials.gov/study/NCT02335905
  3. https://clinicaltrials.gov/study/NCT01701219
  4. https://clinicaltrials.gov/study/NCT03025841
  5. https://clinicaltrials.gov/study/NCT04198571
  6. https://clinicaltrials.gov/study/NCT02806882
  7. https://clinicaltrials.gov/study/NCT02600793
  8. https://clinicaltrials.gov/study/NCT02424734
  9. https://clinicaltrials.gov/study/NCT01664065
  10. https://clinicaltrials.gov/study/NCT00509106
  11. https://clinicaltrials.gov/study/NCT03771313